| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6068123 | The Journal of Allergy and Clinical Immunology: In Practice | 2016 | 13 Pages |
Abstract
The evidence-based threshold for MCID determination for AR studies should supersede the threshold recommended in the AHRQ report.
Keywords
AHRQGRCsAzeinahTNSSSublingual allergen immunotherapySLITSARLTRAMCIDiNCsBDPVASAzelastineLeukotriene receptor antagonistLORAgency for Healthcare Research and Qualitystandard deviationOlopatadineBeclomethasone dipropionateRandomizedMinimal Clinically Important DifferencebaselineTreatmentDouble blindAllergic rhinitisMedical Subject HeadingFluticasone propionateSeasonal allergic rhinitisLoratadineMoMMeshvisual analog scalemometasone furoate nasal sprayMONMontelukastMillimeterSymptomsPlacebo controlledPlacebomulticenterIntranasal corticosteroidonce daily
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Eli O. MD, Dana MD, Mark MD, Lucy MA,